Iressa (ZD1839)

DRUG2 trials

Sponsors

Massachusetts General Hospital, Dartmouth-Hitchcock Medical Center

Conditions

Nonresectable Adrenocortical CarcinomaOvarian CancerPeritoneal CarcinomaTubal Carcinoma

Phase 2

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

CompletedNCT00181688

Massachusetts General HospitalOvarian Cancer, Peritoneal Carcinoma, Tubal Carcinoma

Start: 2003-10-31End: 2006-03-31Target: 35Updated: 2012-12-05

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

CompletedNCT00215202

Dartmouth-Hitchcock Medical CenterNonresectable Adrenocortical Carcinoma

Start: 2004-08-31End: 2007-01-31Updated: 2018-05-17